WO2013090799A1 - Silicon-containing fumaric acid esters - Google Patents
Silicon-containing fumaric acid esters Download PDFInfo
- Publication number
- WO2013090799A1 WO2013090799A1 PCT/US2012/069872 US2012069872W WO2013090799A1 WO 2013090799 A1 WO2013090799 A1 WO 2013090799A1 US 2012069872 W US2012069872 W US 2012069872W WO 2013090799 A1 WO2013090799 A1 WO 2013090799A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- compounds
- methyl
- aryl
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title abstract description 17
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 title abstract description 7
- 229910052710 silicon Inorganic materials 0.000 title abstract description 7
- 239000010703 silicon Substances 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 160
- 125000003118 aryl group Chemical group 0.000 claims description 48
- -1 methoxy, ethoxy, methyl Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 19
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 13
- 230000004770 neurodegeneration Effects 0.000 claims description 13
- 230000003959 neuroinflammation Effects 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- JETSOFMWNXQIQA-AATRIKPKSA-N 1-o-methyl 4-o-(trimethoxysilylmethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC[Si](OC)(OC)OC JETSOFMWNXQIQA-AATRIKPKSA-N 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- ZYPDERWPXAOYKM-DVJWZOGQSA-N 4-o-[bis[[(e)-4-methoxy-4-oxobut-2-enoyl]oxy]-methylsilyl] 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)O[Si](C)(OC(=O)\C=C\C(=O)OC)OC(=O)\C=C\C(=O)OC ZYPDERWPXAOYKM-DVJWZOGQSA-N 0.000 claims description 3
- KKOWGDPEXLGPOS-GGWOSOGESA-N (E)-4-[[[(E)-3-carboxyprop-2-enoyl]oxymethyl-dimethylsilyl]methoxy]-4-oxobut-2-enoic acid Chemical compound OC(=O)/C=C/C(=O)OC[Si](C)(C)COC(=O)\C=C\C(O)=O KKOWGDPEXLGPOS-GGWOSOGESA-N 0.000 claims description 2
- JMJLMVYJKPMZOF-NSCUHMNNSA-N 1-o-methyl 4-o-(trihydroxysilylmethyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OC[Si](O)(O)O JMJLMVYJKPMZOF-NSCUHMNNSA-N 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 239000000203 mixture Substances 0.000 description 17
- 229960004419 dimethyl fumarate Drugs 0.000 description 16
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 description 16
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 description 16
- 229940005650 monomethyl fumarate Drugs 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 11
- 230000004112 neuroprotection Effects 0.000 description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 8
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 229940125797 compound 12 Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 7
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 7
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000001530 fumaric acid Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000002961 luciferase induction Methods 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 0 CC1C2C(C)(CCCC3CCCCC3)CC2CCC*1 Chemical compound CC1C2C(C)(CCCC3CCCCC3)CC2CCC*1 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 101150102665 CCL20 gene Proteins 0.000 description 3
- 101150031350 Cxcl2 gene Proteins 0.000 description 3
- 101150102927 Cxcl3 gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 101150005894 GCLC gene Proteins 0.000 description 3
- 101150037699 GSTA2 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100369986 Mus musculus Tnfaip2 gene Proteins 0.000 description 3
- 101150091206 Nfkbia gene Proteins 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 101150096281 gsta3 gene Proteins 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000003061 neural cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003376 silicon Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 208000037875 astrocytosis Diseases 0.000 description 2
- 230000007341 astrogliosis Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 2
- 239000005052 trichlorosilane Substances 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- AVOMWPMEJVGTKP-OWOJBTEDSA-N (E)-4-oxo-4-(trihydroxysilylmethoxy)but-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)OC[Si](O)(O)O AVOMWPMEJVGTKP-OWOJBTEDSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AJVVKLRCOHWRKD-UHFFFAOYSA-N 1-adamantylsilane Chemical class C1C(C2)CC3CC2CC1([SiH3])C3 AJVVKLRCOHWRKD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- YHFFINXFNYQPQA-UHFFFAOYSA-N 4-[diethoxy(methyl)silyl]butan-1-amine Chemical compound CCO[Si](C)(OCC)CCCCN YHFFINXFNYQPQA-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000003737 Bright-Glo Luciferase Assay System Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- YHMHMHBNRNWWTN-UHFFFAOYSA-N CC(OCC[N](C)(C)OC(C)=O)=O Chemical compound CC(OCC[N](C)(C)OC(C)=O)=O YHMHMHBNRNWWTN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102000007561 NF-E2-Related Factor 2 Human genes 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052057 Neuroborreliosis Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005716 Subacute Combined Degeneration Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100031797 Sulfiredoxin-1 Human genes 0.000 description 1
- 101710091276 Sulfiredoxin-1 Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FYTPGBJPTDQJCG-UHFFFAOYSA-N Trichloro(chloromethyl)silane Chemical compound ClC[Si](Cl)(Cl)Cl FYTPGBJPTDQJCG-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- RQVFGTYFBUVGOP-UHFFFAOYSA-N [acetyloxy(dimethyl)silyl] acetate Chemical compound CC(=O)O[Si](C)(C)OC(C)=O RQVFGTYFBUVGOP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- PCTNMKPNTOXONV-UHFFFAOYSA-N chloroform silane Chemical compound [SiH4].ClC(Cl)Cl PCTNMKPNTOXONV-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- GNEPOXWQWFSSOU-UHFFFAOYSA-N dichloro-methyl-phenylsilane Chemical compound C[Si](Cl)(Cl)C1=CC=CC=C1 GNEPOXWQWFSSOU-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000005055 methyl trichlorosilane Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- JLUFWMXJHAVVNN-UHFFFAOYSA-N methyltrichlorosilane Chemical compound C[Si](Cl)(Cl)Cl JLUFWMXJHAVVNN-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011945 regioselective hydrolysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- ZOYFEXPFPVDYIS-UHFFFAOYSA-N trichloro(ethyl)silane Chemical compound CC[Si](Cl)(Cl)Cl ZOYFEXPFPVDYIS-UHFFFAOYSA-N 0.000 description 1
- ORVMIVQULIKXCP-UHFFFAOYSA-N trichloro(phenyl)silane Chemical compound Cl[Si](Cl)(Cl)C1=CC=CC=C1 ORVMIVQULIKXCP-UHFFFAOYSA-N 0.000 description 1
- BIBZKNXZTAKPDB-UHFFFAOYSA-N trichloro-(2,3-dichlorophenyl)silane Chemical compound ClC1=CC=CC([Si](Cl)(Cl)Cl)=C1Cl BIBZKNXZTAKPDB-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1896—Compounds having one or more Si-O-acyl linkages
Definitions
- the present invention provides a compound of Formula III: or a pharmaceutically acceptable salt thereof, wherein:
- R 2 is C1-C10 alkyl.
- the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula I:
- the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula II: ( ⁇ )
- the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula III: or a pharmaceutically acceptable salt thereof, wherein:
- R 1 is C1-C24 alkyl or C 6 -Cio aryl
- each of m, n, and r, independently, is 0-4;
- R 3 , R 4 , and R 5 are [0026] Another group of compounds of Formula I include compounds wherein R is optionally substituted C1-C24 alkyl. Another group of compounds of Formula I include compounds wherein R 1 is optionally substituted Ci-C 6 alkyl. Another group of compounds of Formula I include compounds wherein R 1 is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula I include compounds wherein R 1 is optionally substituted C5-C50 aryl. Another group of compounds of Formula I include compounds wherein R 1 is optionally substituted C5-C10 aryl. Another group of compounds of Formula I include compounds wherein R is C1-C10 alkyl.
- compounds of Formula II include compounds wherein each of R and R is, independently, optionally substituted C5-C10 aryl.
- R 1 is C1-C24 alkyl or C5-C50 aryl
- fumaric acid ester 1 can be prepared by reacting alcohol (R ! -OH) under the coupling conditions of hydroxybenzotriazole (HOBT), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCl), and diisopropyl amine (DIPEA) as shown in Scheme 3.
- HOBT hydroxybenzotriazole
- EDCl l-ethyl-3-(3- dimethylaminopropyl)carbodiimide
- DIPEA diisopropyl amine
- the compounds of this invention of Formula III may be prepared by the exemplary reaction in Scheme 7.
- expression of the gene is measured by determining the expression level of an mR A for that gene.
- expression of the gene is measured by determining the expression level of a protein product encoded by the gene.
- the protein product is measured in cerebrospinal fluid or blood (e.g., plasma) of the subject.
- expression level is measured at least at one time point selected from prior to initiation of treatment, during treatment, and after treatment.
- the amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, and the particular mode of administration. It should be understood, however, that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredient can also depend upon the therapeutic or prophylactic agent, if any, with which the ingredient is co-administered.
- the compounds and pharmaceutical compositions of the invention can be administered in an amount ranging from about 1 mg/kg to about 50 mg/kg (e.g., from about 2.5 mg/kg to about 20 mg/kg or from about 2.5 mg/kg to about 15 mg/kg).
- the amount of the compounds and pharmaceutical compositions of the invention administered will also vary, as recognized by those skilled in the art, dependent on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- the pharmaceutical preparations comprise a capsule containing the compound or pharmaceutical composition of the present invention in the form of an enteric-coated microtablet.
- the coating of the microtablet may be composed of different layers.
- the first layer may be a methyacrylic acid - methyl methacrylate copolymer/isopropyl solution which isolates the tablet cores from potential hydrolysis from the next applied water suspensions.
- the enteric coating of the tablet may then be conferred by an aqueous methacrylic acid - ethyl acrylate copolymer suspension.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to silicon-containing fumaric acid esters of the Formulae I-IV. The silicon- containing fumaric acid esters of Formulae I-IV are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases. (I), (II), (III) & (IV)
Description
SILICON-CONTAINING FUMARIC ACID ESTERS
BRIEF SUMMARY OF THE INVENTION
[0001] The methods provided are exemplary and are not intended to limit the scope of the claimed embodiments.
[0002] In one embodiment, the present invention provides a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R is Ci-Cio alkyl, C6-Cio aryl, hydroxyl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl;
each of R3, R4, and R5, independently, is C1-C10 alkyl, C6-Cio aryl, hydroxyl,
wherein R is C1-C24 alkyl or C6-Cio aryl; each of which can be optionally substituted; and
each of m, n, and r, independently, is 0-4;
[0003] In another embodiment, the present invention provides a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C24 alkyl or C6-Cio aryl; and
2 3
each of, independently, R and R , is C1-C10 alkyl or C6-Cio aryl.
[0004] In one embodiment, the present invention provides a compound of Formula II, wherein R1 is methyl, ethyl, or isopropyl. In another embodiment, the present invention provides a compound of Formula II wherein each of R 2 and R 3 , independently, is methyl, ethyl, or isopropyl.
[0005] In another embodiment, the present invention provides a compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C24 alkyl or C6-Cio aryl;
2 3 5
each of R , R , and R , independently, is hydroxyl, C1-C10 alkyl, C6-Cio aryl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl; and
n is 1 or 2.
[0006] In one embodiment, the present invention provides a compound of Formula III, wherein each of R 2 , R 3 , and R 5 , independently, is hydroxyl, methyl, or ethyl. In another embodiment, the present invention provides a compound of Formula III, wherein n is 1.
[0007] In another embodiment, the present invention provides a compound of Formula IV:
R1 is C1-C24 alkyl or C6-Cio aryl; and
R2 is C1-C10 alkyl.
[0008] In one embodiment, the present invention provides a compound of Formula IV, wherein each R1, independently, is is methyl, ethyl, or isopropyl. In another embodiment, the present invention provides a compound of Formula IV, wherein R is methyl, ethyl, or isopropyl.
[0009] In another embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Formula I, Formula II, Formula III, Formula IV, or mixtures thereof.
[0010] In another embodiment, the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R is Ci-Cio alkyl, C6-Cio aryl, hydroxyl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl;
each of R3, R4, and R5, independently, is C1-C10 alkyl, C6-Cio aryl, hydroxyl, -O- C1-C10 alkyl, -O-C6-C10 aryl, or
wherein R is C1-C24 alkyl or C6-Cio aryl; each of which can be optionally substituted; and
each of m, n, and r, independently, is 0-4;
[0011] In another embodiment, the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula II:
(Π)
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C24 alkyl or C6-Cio aryl; and
2 3
each of, independently, R and R , is C1-C10 alkyl or C6-Cio aryl.
[0012] In another embodiment, the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-C24 alkyl or C6-Cio aryl;
2 3 5
each of R , R , and R , independently, is hydroxyl, C1-C10 alkyl, C6-Cio aryl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl; and
n is 1 or 2.
[0013] In another embodiment, the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of Formula IV:
R1 is C1-C24 alkyl or C6-Cio aryl; and
R2 is Ci-Ci0 alkyl.
[0014] In one embodiment, the present invention provides a method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation wherein the condition is multiple sclerosis, Huntington's disease, Amyotrophic lateral sclerosis, Alzheimer's disease, or Parkinson's disease by administering a compound of Formula I, Formula II, Formula III, or Formula IV.
[0015] In one embodiment, the present invention provides a compound of Formula I selected from the group consisting of: (dimethylsilanediyl)dimethyl difumarate, methyl ((trimethoxysilyl)methyl) fumarate, methyl ((trihydroxysilyl)methyl) fumarate, and trimethyl (methylsilanetriyl) trifumarate.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIGURE la provides the luciferase induction fold change after 24 hours of stimulation with the compounds dimethyl fumarate (DMF), monomethyl fumarate (MMF), (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11), and methyl ((trimethoxysilyl)methyl) fumarate (Compound 12) based on compound concentration in the DLD-1/ARE-E2 cell reporter cell line.
[0017] FIGURE lb provides the luciferase induction fold change after 48 hours of stimulation with the compounds dimethyl fumarate (DMF), monomethyl fumarate (MMF), (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11), and methyl ((trimethoxysilyl)methyl) fumarate (Compound 12) based on compound concentration in the DLD-1/ARE-E2 cell reporter cell line.
[0018] FIGURE 2a provides the luciferase induction fold change after 24 hours of stimulation with the compounds dimethyl fumarate (DMF), monomethyl fumarate (MMF), (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11), and methyl ((trimethoxysilyl)methyl) fumarate (Compound 12) based on compound concentration in the MCF7/ARE-D3 cell reporter cell line.
[0019] FIGURE 2b provides the luciferase induction fold change after 48 hours of stimulation with the compounds dimethyl fumarate (DMF), monomethyl fumarate (MMF), (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11), and methyl
((trimethoxysilyl)methyl) fumarate (Compound 12) based on compound concentration in the MCF7/ARE-D3 cell reporter cell line.
[0020] FIGURE 3 provides the luciferase induction fold change after 24 hours of stimulation with the compounds dimethyl fumarate (DMF), monomethyl fumarate (MMF), (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11), and methyl ((trimethoxysilyl)methyl) fumarate (Compound 12) based on compound concentration in the MCF7/ARE-D3 cell reporter cell line.
DETAILED DESCRIPTION OF THE INVENTION
[0021] Dimethyl fumarate (DMF) has been shown to have significant therapeutic effects on patients having multiple sclerosis. See, e.g., Kappos et al, Lancet 572: 1463-1472 (2008) and Nature Drug Reviews 10:404 (2011). Preclinical studies indicate that the therapeutic effects of DMF appear to be mediated through activation of the nuclear factor- E2-related factor 2 (Nrf2) transcriptional pathway, which is a major pathway to combat oxidative stress associated with several different neurological diseases (see, e.g., WO 2008/097596 and Calkins et al., Antioxid. Redox Signal 77^:497-508 (2009)). DMF is rapidly metabolized into monomethyl fumarate (MMF) upon administration. The present invention discloses silicon-containing compounds, which like DMF, can metabolize into MMF upon administration.
[0022] The silicon atom, although similar to carbon, has a larger covalent radius (¾ = 117 pm) than carbon (rc = 77 pm) and therefore forms longer and slightly more flexible bonds which result in subtle changes in molecular size and shape of the silicon analogs. Furthermore, silicon is more electropositive which causes a slight change in bond polarization. These differences affect how silicon analogs interact with enzymes and proteins which could give rise to different pharmacological effects and metabolism. For example, sila-haloperidol has shown lack of a major pyridinium metabolite, wherein this metabolite was directly linked to neurotoxic side effects observed by the carbon analog haloperidol. Johansson, T., et al, Drug Metabolism & Disposition 35:73-83 (2010).
[0023] Additionally, the fact that silicon is more electropositive would make it possible to differentiate between the two ester groups in the disclosed fumarate molecules. This would allow for regioselective hydrolysis of the silicon-containing ester group to occur and would unmask the active drug ingredient.
[0024] Silicon analogs are in general more lipophilic. A small increase in lipophilicity will markedly increase the absorption, volume of distribution, and tissue penetration of a drug, leading to a lesser degree of hepatic metabolism and enhance the plasma half-life of a drug. In addition, increasing lipophilicity may also improve the permeability through the blood brain barrier, enhancing central nervous system activity. See Pooni, P.K., et al., Mini-Reviews in Med. Chem. (5: 1 169-1 177 (2006). The silyl group confers lipophilicity that can enhance the penetration of the compounds across the gut wall, cell membranes, and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and pharmacokinetics.
[0025] The present invention provides silicon-containing fumaric acid esters represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R is Ci-Cio alkyl, C5-Ci5 aryl, hydroxyl, -O-Ci-Cio alkyl, or -O-C5-C15 aryl;
each of R3, R4, and R5, independently, is Ci-Cio alkyl, C5-C15 aryl, hydroxyl, -O- C1-C10 alkyl, -O-C5-C15 aryl, or
wherein R is C1-C24 alkyl or C5-C50 aryl; each of which can be optionally substituted; and
each of m, n, and r, independently, is 0-4;
provided that at least one of R3, R4, and R5 is
[0026] Another group of compounds of Formula I include compounds wherein R is optionally substituted C1-C24 alkyl. Another group of compounds of Formula I include compounds wherein R1 is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula I include compounds wherein R1 is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula I include compounds wherein R1 is optionally substituted C5-C50 aryl. Another group of compounds of Formula I include compounds wherein R1 is optionally substituted C5-C10 aryl. Another group of compounds of Formula I include compounds wherein R is C1-C10 alkyl. Another group of compounds of Formula I include compounds wherein R is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula I include compounds wherein R is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula I include compounds wherein R is optionally substituted C5-C15 aryl. Another group of compounds of Formula I include compounds wherein R is optionally substituted C5-C10 aryl.
[0027] In another embodiment, the invention provides compounds represented by Formula
II:
2
each of, independently, R and R , is C1-C10 alkyl or C5-C15 aryl.
2
R" and RJ can be the same or different, can be optionally substituted, and independently can be selected from the group consisting of C1-C10 alkyl or C5-C15 aryl.
[0028] In another embodiment, compounds of Formula II include compounds wherein R1 is optionally substituted C1-C24 alkyl. Another group of compounds of Formula II include compounds wherein R1 is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula II include compounds wherein R1 is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula II include compounds wherein R1 is optionally substituted C5-C50 aryl. Another group of compounds of Formula II include compounds wherein R1 is optionally substituted C5-C10 aryl. alkyl. Another
2 3 group of compounds of Formula II include compounds wherein each of R and R is, independently, optionally substituted Ci-Cio alkyl. Another group of compounds of
Formula II include compounds wherein each of R 2 and R 3 is, independently, optionally substituted Ci-C6 alkyl. Another group of compounds of Formula II include compounds wherein each of R 2 and R 3 is, independently, optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula II include compounds wherein each of R 2 and R 3 is, independently, optionally substituted C5-Ci5 aryl. Another group of
2 3 compounds of Formula II include compounds wherein each of R and R is, independently, optionally substituted C5-C10 aryl.
[0029] In another embodiment, the invention provides compounds represented by Formula
R1 is C1-C24 alkyl or C5-C50 aryl;
2 3 5
each of R , R , and R , independently, is hydroxyl, C1-C10 alkyl, C5-C15 aryl, -O-Ci-Cio alkyl, or -O-C5-C15 aryl; and
n is 1 or 2.
[0030] In another embodiment, compounds of Formula III include compounds wherein R1 is optionally substituted C1-C24 alkyl. Another group of compounds of Formula III include compounds wherein R1 is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula III include compounds wherein R1 is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula III include compounds wherein R1 is optionally substituted C5-C50 aryl. Another group of compounds of Formula III include compounds wherein R1 is optionally substituted C5-C10 aryl.
2 3
Another group of compounds of Formula III include compounds wherein each of R , R , and R5 is, independently, hydroxyl. Another group of compounds of Formula III include
2 3 5
compounds wherein each of R , R , and R is, independently, optionally substituted Ci- C10 alkyl. Another group of compounds of Formula III include compounds wherein each
2 3 5
of R , R , and R is, independently, optionally substituted Ci-C6 alkyl. Another group of
2 3 5 compounds of Formula III include compounds wherein each of R , R , and R is,
independently, optionally substituted methyl, ethyl, or isopropyl. Another group of
2 3 5 compounds of Formula III include compounds wherein each of R , R , and R is, independently, optionally substituted C5-Ci5 aryl. Another group of compounds of
Formula III include compounds wherein each of R 2 , R 3 , and R 5 is, independently, optionally substituted C5-C10 aryl.
[0031] In another embodiment, the invention provides compounds represented by Formula
IV:
R1 is C1-C24 alkyl or C5-C50 aryl; and
R2 is C1-C10 alkyl.
[0032] In another embodiment, compounds of Formula IV include compounds wherein R1 is optionally substituted C1-C24 alkyl. Another group of compounds of Formula IV include compounds wherein R1 is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula IV include compounds wherein R1 is optionally substituted methyl, ethyl, or isopropyl. Another group of compounds of Formula IV include compounds wherein R1 is optionally substituted C5-C50 aryl. Another group of compounds of Formula IV include compounds wherein R1 is optionally substituted C5-C10 aryl. Another group of compounds of Formula IV include compounds wherein R is optionally substituted Ci-C6 alkyl. Another group of compounds of Formula IV include compounds wherein R is optionally substituted methyl, ethyl, or isopropyl.
[0033] The term "alkyl" as employed herein by itself or as part of another group refers to both straight and branched chain radicals of up to 24 carbons. Alkyl groups include straight- chained and branched C1-C24 alkyl groups, e.g., C1-C10 alkyl groups. C1-C10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, heptyl, 1 -methylhexyl, 2-ethylhexyl, 1 ,4-dimethylpentyl, octyl, nonyl, and decyl. Unless otherwise indicated, all alkyl groups described herein include both
unsubstituted and substituted alkyl groups. Further, each alkyl group can include its deuterated counterparts.
[0034] The term "aryl" as employed herein by itself or as part of another group refers to monocyclic, bicyclic, or tricyclic aromatic groups containing from 5 to 50 carbons in the ring portion. Aryl groups include C5-15 aryl, e.g., phenyl, p-tolyl, 4-methoxyphenyl, 4- (tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 3- nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 4-acetamidophenyl, 2-methyl-3- acetamidophenyl, 2-methyl-3-aminophenyl, 3-methyl-4-aminophenyl, 2-amino-3- methylphenyl, 2,4-dimethyl-3-aminophenyl, 4-hydroxyphenyl, 3-methyl-4- hydroxyphenyl, 1-naphthyl, 3-amino-naphthyl, 2-methyl-3-amino-naphthyl, 6-amino-2- naphthyl, 4,6-dimethoxy-2-naphthyl, indanyl, biphenyl, phenanthryl, anthryl, and acenaphthyl. Unless otherwise indicated, all aryl groups described herein include both unsubstituted and substituted aryl groups.
[0035] Optional substituents on the alkyl group include one or more substituents independently selected from halogen, hydroxyl, carboxyl, amino, nitro, or cyano.
[0036] Optional substituents on the aryl group include one or more substituents independently selected from alkyl, alkoxy, halogen, hydroxyl, or amino.
[0037] Halogen groups include fluorine, chlorine, bromine, and iodine.
[0038] Some of the compounds of the present invention may exist as stereoisomers including optical isomers. The invention includes all stereoisomers and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well-known to those of ordinary skill in the art.
[0039] The compounds of the invention may be prepared using methods known to those skilled in the art, or the novel methods of this invention.
[0040] Specifically, the compounds of this invention of Formula I may be prepared by the exemplary reaction in Scheme 1.
Scheme 1
[0041] Reaction of fumaric acid ester 1 with silane diacetate intermediate 2 in a refluxing organic solvent such as diethyl ether, toluene, or hexane to give the desired siloxane 3.
[0042] Some of the fumaric acid esters 1 are commercially available. Fumaric acid ester 1 can also be prepared, for example, using synthetic methods known by one of ordinary skill in the art. For example, fumaric acid can be converted by reacting alcohol (R!-OH) with a catalytic amount of p-toluene sulfonic acid at room temperature for a few hours to overnight as shown in Scheme 2.
Scheme 2
[0043] Alternatively, fumaric acid ester 1 can be prepared by reacting alcohol (R!-OH) under the coupling conditions of hydroxybenzotriazole (HOBT), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDCl), and diisopropyl amine (DIPEA) as shown in Scheme 3.
Scheme 3
[0044] Some of the silanes that can be used in the present invention are commercially available. Commercially available silyl halides include trimethylsilyl chloride, dichloro- methylphenylsilane, dimethyldichlorosilane, methyltrichlorosilane, (4- aminobutyl)diethoxymethylsilane, trichloro(chloromethyl)silane, trichloro(dichlorophenyl)silane, trichloroethylsilane, trichlorophenylsilane, and trimethylchlorosilane. Commercial sources for silyl halides include Sigma Aldrich and Acros Organics.
[0045] Silanes used in the present invention can be prepared, for example, using synthetic methods known by one of ordinary skill in the art. For example, trichlorosilane may be prepared by the exemplary reaction in Scheme 4.
Scheme 4
R CI
R ^ + HSiCI ^ ¾r
^ 3 C Ι
[0046] The silylation of styrene derivatives catalyzed by palladium is described in Zhang,
F. and Fan, Q.-H., Organic & Biomolecular Chemistry 7 1Q- 1 (2009) and in Bell,
J.R., et al, Tetrahedron 65:9368-9372 (2009).
[0047] Diacetate intermediate 2 may be prepared by treatment of dichlorosubstituted silicon compound 4 with sodium acetate in diethyl ether under reflux as shown in Scheme
5.
Scheme 5
CI R2 NaOAc Et20 AcO R2
- sr
C 'R3 reflux AcQf 'R3 wherein R 2 and R 3 are each defined above for Formula I.
[0048] Specifically, the compounds of this invention of Formula III may be prepared by the exemplary reaction in Scheme 6.
Scheme 6
[0049] Fumaric acid ester 1 can be converted to the sodium salt 5 using, for example, sodium methoxide in methanol at room temperature. Removal of the solvent would afford sodium salt 5. Treatment of the sodium salt 5 with silane 6 in an organic solvent such as dimethylformamide under reflux would generate ester 7. The synthesis of structurally related (trimethoxysilyl) -methyl esters is described in Voronkov, M.G., et al., Zhurnal Obshchei Khimii 52:2052-2055 (1982).
[0050] Alternatively, the compounds of this invention of Formula III may be prepared by the exemplary reaction in Scheme 7.
Scheme 7
base, heat
(Ill) wherein R1, R4, R5, R6, and n are as defined above for Formula III.
[0051] Treatment of the sodium salt 5 with silane 6 in an organic solvent such as dimethylformamide under heating with or without an acid scavenger would generate ester 7.
Scheme 8
wherein R1, R4, R5, R6, and n are as defined above for Formula III.
[0052] Reaction of fumaric acid ester 1 with tri-substituted silane alcohol 8 in methylene chloride with mild base such as triethyl amine and 4-N,N-dimethyl amino pyridine (DMAP) at room temperature generates fumarate 7. See Coelho, P.J., et al., Eur. J. Org. Chem. 3039-3046 (2000).
[0053] Specifically, the compounds of this invention of Formula IV can be prepared by emplary reaction in Scheme 9.
Scheme 9
10
1 2
wherein R and R are as defined above for Formula IV.
[0054] Reaction of fumaric acid 1 with trichlorosilane 9 in a refluxing organic solvent such as hexane or toluene using a catalytic amount of a base such as triethylamine generates the trifumarate silane 10. The reaction of acetic and methacrylic acids with 1- silyladamantanes is described in Fedotov, N.S., et al., Zhurnal Obshchei Khimii 52: 1837- 1842 (1982).
[0055] The present invention includes a therapeutic method comprising administering to an animal an effective amount of a compound of Formulae I-IV, or a pharmaceutically acceptable salt of said compound of Formulae I-IV, wherein said therapeutic method is useful for treating a subject having a condition or at risk of having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation. A condition characterized by at least one of neurodegeneration and neuroinflammation is a condition in which either or both of those processes leads to a failure of the subjects nervous system to function normally. The loss of normal function may be located in either or both of the central nervous system or it can affect the immune system in general (e.g., the brain or spinal cord) and the peripheral nervous system or it can affect the immune system in general (e.g., in circulation and in tissues). Examples of such conditions include, but are not limited to, Adrenal Leukodystrophy (ALD), Alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjorgren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cerebral palsy, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt- Jakob disease, Familial Fatal Insomnia, Frontotemporal lobar degeneration,
Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primay lateral sclerosis, Prion diseases, Progressive Supranuclear Palsy, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia, Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, Toxic encephalopathy, LHON (Leber's Hereditary optic neuropathy), MELAS (Mitochondrial Encephalomyopathy; Lactic Acidosis; Stroke), MERRF (Myoclonic Epilepsy; Ragged Red Fibers), PEO (Progressive External Opthalmoplegia), Leigh's Syndrome, MNGIE (Myopathy and external ophthalmopolegia; Neuropathy; Gastro-Intestinal; Encephalopathy), Kearns-Sayre Syndrome (KSS), NARP, Hereditary Spastic Paraparesis, Mitochondrial myopathy, and Friedreich Ataxia.
[0056] In one embodiment, the condition is multiple sclerosis. In another embodiment, the condition is relapsing-remitting multiple sclerosis. In another embodiment, the condition is secondary-progressive multiple sclerosis. In another embodiment, the condition is primary-progressive multiple sclerosis. In another embodiment, the condition is progressive-relapsing multiple sclerosis.
[0057] In one embodiment, the condition is Amyotrophic lateral sclerosis (ALS).
[0058] In one embodiment, the condition is Huntington's disease.
[0059] In one embodiment, the condition is Parkinson's disease.
[0060] In one embodiment, the condition is Alzheimer's disease.
[0061] In some embodiments, administration of at least one compound or pharmaceutically acceptable salt thereof, as described herein, to a patient gives rise to "neuroprotection," or said another way, the effect of administering the compound to the patient is neuroprotection. Neuroprotection comprises at least one of maintenance, salvage, recovery, and regeneration of the nervous system, its cells, structure, and function following injury or damage. In some embodiments, neuroprotection comprises at least one of primary neuroprotection and secondary neuroprotection. "Primary neuroprotection" is protection comprising direct modulation of the structure and/or function of neural cells residing within the CNS (at least one cell type selected from neurons, oligodendrocytes, astrocytes, and microglia). "Secondary neuroprotection" is
protection comprising modulation of the structure or function of at least one cell type that typically resides outside the CNS (e.g. immune cells). In secondary neuroprotection, the at least one compound or pharmaceutically acceptable salt thereof acts directly or indirectly on the at least one cell type that typically resides outside the CNS to modulate the structure and/or function of the at least one cell type. The at least one cell type then modulates, directly or otherwise, the structure and/or function of neural cells residing within the CNS (at least one cell type selected from neurons, oligodendrocytes, astrocytes, and microglia). In some embodiments, neuroprotection comprises a lessening of the severity or rate of neurodegeneration or neuroinflammation in a subject. "Maintenance" of the nervous system, its cells, structure, and function comprises embodiments in which the at least one compound or pharmaceutically acceptable salt thereof is administered to a subject prior to development of at least one sign or symptom of a disease or condition disclosed herein and reduces the eventual severity of the disease or condition and/or reduces the rate of onset of the disease and/or condition.
[0062] In some embodiments, the condition to be treated is characterized by increased expression of pro-inflammatory genes, such as in neural cells of the subject. In the case of a subject experiencing astrogliosis, for example, expression of at least one proinflammatory gene selected from Ccl20, Ccl3, Ccl4, Cxcll, CxcllO, Cxcl2, Cxcl3, Cxcl6, ILla, Illb, TNF, Ifit3, Nfkbia, Nfkbiz, Tnfaip2, and Zc3hl2a is increased in the subject. In some embodiments, administration of at least a compound, or a pharmaceutically acceptable salt thereof, as described herein, to the subject, results in suppression of expression of at least one gene selected from Ccl20, Ccl3, Ccl4, Cxcll, CxcllO, Cxcl2, Cxcl3, Cxcl6, ILla, Illb, TNF, Ifit3, Nfkbia, Nfkbiz, Tnfaip2, and Zc3hl2a.
[0063] Certain examples of neuroprotective genes are also disclosed herein, namely
Gsta2, Gsta3, Gclc, Ggtl, Txnrdl, Srxnl, Sqstml, and NQOl . In some embodiments, administration of at least one compound or pharmaceutically acceptable salt thereof, as described herein, to the subject, results in an up-regulation of at least one gene selected from Gsta2, Gsta3, Gclc, Ggtl, Txnrdl, Srxnl, Sqstml, and NQOl .
[0064] The term "therapeutically effective amount" refers to that amount of a compound or pharmaceutically acceptable salt thereof which results in prevention or delay of onset or amelioration of at least one symptom of a condition characterized by neurodegeneration or neuroinflammation in a subject, or an attainment of a desired biological outcome, such as reduced astrogliosis.
[0065] In some embodiments, the expression level of at least one gene selected from
Ccl20, Ccl3, Ccl4, Cxcll, CxcllO, Cxcl2, Cxcl3, Cxcl6, ILla, Illb, TNF, Ifit3, Nfkbia, Nfkbiz, Tnfaip2, Zc3hl2a, Gsta2, Gsta3, Gclc, Ggtl, Txnrdl, Srxnl, Sqstml, and NQOl is measured in a subject. In some embodiments, expression of the gene is measured by determining the expression level of an mR A for that gene. In some embodiments, expression of the gene is measured by determining the expression level of a protein product encoded by the gene. In some embodiments, the protein product is measured in cerebrospinal fluid or blood (e.g., plasma) of the subject. In some embodiments, expression level is measured at least at one time point selected from prior to initiation of treatment, during treatment, and after treatment.
[0066] The ability of compounds of the present invention to activate the Nrf-2 antioxidant response pathway can be tested according to Example 5 below. The compounds can also be evaluated in other cell based assays or animal model(s) of neuroinflammatory and neurodegenerative diseases. For example, compounds of the present invention can be evaluated for their ability to treat ALS in a cell-based motor neuron survival assay as described in Haidet-Phillips et al, Nat Biotechnol. 2P(¾):824-828 (201 1). For animal model studies, compounds of the present invention can be investigated in models for Alzheimer's disease (see Dumont et al, J. Neurochem. 109(2):502-512 (2009)), Parkinson's disease (see Jakel et al., Brain Res. 1144: 192-201 (2007)), ALS (see Wegorzewska et al., Proc. Natl. Acad. Sci. US A. 706^: 18809-14 (2009); Wong et al, Neuron 14(6): 1105-1116 (1995); and Vargas et al, J. Neurosci. 25^: 13574-13581 (2008)), Huntington's disease (see Stack et al, Free Radic. Biol. Med. 49(2): \47-\58 (2010)), and MS (the Experimental Autoimmune Encephalomyelitis (EAE) model; see, e.g., Tuohy et al, J. Immunol. 747: 1126-1130 (1988), Sobel et al, J. Immunol. 752:2393-2401 (1984), and Traugott, Cell Immunol. 77M 14-129 (1989)).
[0067] The term "treating" refers to administering a therapy in an amount, manner, and/or mode effective to prevent or delay onset of or amelioration of at least one symptom of a condition characterized by neurodegeneration or neuroinflammation in a subject, to either a statistically significant degree or to a degree detectable to one skilled in the art. An effective amount, manner, or mode can vary depending on the subject and may be tailored to the subject. For neurological disorders referred herein, the treatment offered by the method of this invention aims at improving the conditions (or lessening the detrimental
effects) of the disorders and not necessarily at completely eliminating or curing the disorders.
[0068] The compounds and pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal, or topical routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
[0069] The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, and the particular mode of administration. It should be understood, however, that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredient can also depend upon the therapeutic or prophylactic agent, if any, with which the ingredient is co-administered.
[0070] In some embodiments, the compounds and pharmaceutical compositions of the invention can be administered in an amount ranging from about 1 mg/kg to about 50 mg/kg (e.g., from about 2.5 mg/kg to about 20 mg/kg or from about 2.5 mg/kg to about 15 mg/kg). The amount of the compounds and pharmaceutical compositions of the invention administered will also vary, as recognized by those skilled in the art, dependent on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents.
[0071] For example, the compounds and pharmaceutical compositions of the invention can be administered to a subject, for example orally, in an amount of from about 0.1 g to about 1 g per day, or for example, in an amount of from about 100 mg to about 800 mg per day.
[0072] The amount of compounds and pharmaceutical compositions of the invention may be administered in separate administrations of 2, 3, 4, 5 or 6 equal doses per day.
[0073] In addition to administering the compound as a raw chemical, the compounds of the invention may be administered as part of a pharmaceutical preparation containing
suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which may be used pharmaceutically. For example, the preparations, particularly those preparations which may be administered orally and which may be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which may be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, contain from about 0.01 to 99 percent, preferably from about 0.25 to 75 percent of active compound(s), together with the excipient.
[0074] Also included within the scope of the present invention are the non-toxic pharmaceutically acceptable salts of the compounds of the present invention. Acid addition salts are formed by mixing a solution of the compound of Formulae I-IV with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate. Acceptable base salts include aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts.
[0075] The pharmaceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention. Foremost among such animals are mammals, e.g., humans and veterinary animals, although the invention is not intended to be so limited.
[0076] The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
[0077] Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium
carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
[0078] In one embodiment, the pharmaceutical preparations comprise a capsule containing the compound or pharmaceutical composition of the present invention in the form of an enteric-coated microtablet. The coating of the microtablet may be composed of different layers. The first layer may be a methyacrylic acid - methyl methacrylate copolymer/isopropyl solution which isolates the tablet cores from potential hydrolysis from the next applied water suspensions. The enteric coating of the tablet may then be conferred by an aqueous methacrylic acid - ethyl acrylate copolymer suspension.
[0100] Other pharmaceutical preparations which may be used orally include push- fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules may contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
[0101] Possible pharmaceutical preparations which may be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a
base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
[0102] Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400), or cremophor, or cyclodextrins. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension and include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
[0103] In accordance with one aspect of the present invention, compounds of the invention are employed in topical and parenteral formulations and are used for the treatment of psoriasis. The topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C12). The preferred carriers are those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers may be employed in these topical formulations.
[0104] Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of oil such as almond oil, is admixed. A typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
[0105] Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.
[0106] Having now generally described this invention, the same will be understood by reference to the following examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.
EXAMPLES
Example 1
Synthesis of (E)-0,0'-(dimethylsilanediyl)dimethyl difumarate (Compound 11)
[0107] Step 1 : Preparation of dimethylsilanediyl diacetate 11B
O
p Et20, reflux, 2 h 0-^~-~
^Sf + NaOAc ^Si'
11A 1 1 B b
[0108] To a slurry of sodium acetate (8.2 g, 100 mmol, 2.0 equiv.) in anhydrous diethyl ether (40 mL) was slowly added a solution of dimethyldichloro silane 11A (6.45 g, 50 mmol, 1.0 equiv.) in anhydrous diethyl ether (10 mL). After addition was completed, the mixture was heated at reflux for 2 hours, and then filtered under N2. The filtrate was concentrated under vacuum at 40 °C to give diacetate 1 IB as a colorless oil (6.1 g, 70%). 1H NMR (400 MHz, CDC13) δ ppm: 2.08 (s, 6H), 0.48 (s, 6H).
[0109] Step 2: Preparation of (^-O,O '- dimethylsilanediyl)dimethyl difumarate 11
11 B 11
[0110] A mixture of 11B (2.0 mL, 12 mmol, 1.5 equiv.) and 11C (1.04 g, 8.0 mmol, 1.0 equiv.) in a sealed tube was heated at 170 °C with stirring under microwave condition for 1 hour. After cooling to 50 °C, the mixture was transferred to a round bottom flask and the excess silica reactant 11B was removed under vacuum at 100 °C to afford compound 11 as brown oil (1.47 g, 60%). 1H NMR (400 MHz, CDC13) δ ppm: 6.82-6.80 (m, 4H), 3.79 (s, 6H), 0.57 (s, 6H).
EXAMPLE 2
Synthesis of methyl ((trimethoxysilyl)methyl) fumarate (Compound 12)
[0111] To a stirred solution of monomethyl fumarate (3.5 g, 27 mmol, 1.0 equiv.) in anhydrous THF (35 mL) at room temperature was added sodium hydride (1.08 g, 27 mmol, 1.0 equiv.) in small portions. After addition, the mixture was heated to reflux for 3 hours, and then cooled to room temperature. The solid was collected by filtration and washed twice with diethyl ether, and further dried in vacuo to give 3.8 g of 12B (93%).
[0112] To a suspension of 12B (760 mg, 5.0 mmol, 1.0 equiv.) in dry DMA (5 mL) at 100
°C under nitrogen was added a solution of 12A (1.03 g, 6.0 mmol, 1.2 equiv.) in dry DMA (1 mL) dropwise. The resulting mixture was heated to 160 °C and stirred for 1 hour, and then cooled to room temperature. The solid was filtered, and the filtrate was evaporated
under reduced pressure to give the titled compound 12, 513 mg (37%), as a red viscous liquid.
[0113] 1H NMR (400 MHz, CDC13) δ ppm: 6.90-6.86 (m, 2H), 3.97 (s, 2H), 3.82 (s, 3H),
3.62 (s, 9H).
EXAMPLE 3
Synthesis of methyl ((trihydroxysilyl)methyl fumarate (Compound 13)
12 13
[0114] To a solution of 12 (1.0 g, 3.8 mmol, 1.0 equiv., prepared in Example 2) in
MeOH (10 mL) at room temperature was added water (341 mg, 19.0 mmol, 5.0 equiv.) dropwise. After addition, the mixture was stirred at room temperature for 30 minutes, with white solids precipitated out. The solids were collected through filtration, washed with methanol three times, and dried at 60 °C in vacuo, to provide the titled compound 13, 500 mg (59%), as a white solid.
[0115] 1H NMR (400 MHz, DMSO- 6) δ ppm: 6.79-6.74 (m, 2H), 3.91-3.58 (m, 6H),
3.18-3.15 (m, 2H).
EXAMPLE 4
Synthesis of trimethyl (methylsilanetriyl) trifumarate (Compound 14)
[0116] Following the procedure described in Scheme 9, monomethyl fumarate 14A would react with trichloromethane-silane 14B in refluxing toluene or hexanes with a catalytic amount of triethylamine to provide (2 Έ, 2 "E)-trimethyl O,O ',O"-(¾iethylsilanetriyl) trifumarate 14C.
EXAMPLE 5
Nrf2 activation cell-based assay
[0117] Human cancer cell line DLD-1 and breast cancer cell line MCF7 reporter stable cell lines were generated by transfection with a firefly luciferase reporter construct harboring the luciferase cDNA cloned downstream of eight catenated copies of the antioxidant response element (ARE: SEQ ID NO.: l).
[0118] To measure Nrf2 activation in the ARE-luciferase reporter cell lines, the cells were plated in 96-well plates at 20-50k cells/well 24 hours prior to stimulation with the test compounds. The test compounds were prepared in dimethylsulfoxide (DMSO) and diluted with culture media to required concentrations (final DMSO concentrations <0.3%). The reporter cells were harvested 24 hours - 48 hours after addition of the compounds and lysed for detection of luciferase activity. Luciferase activity in the lysates was monitored using the Bright-Glo Luciferase Assay System of Promega and Tecan Genios Pro plate reader.
[0119] Luciferase induction in the compound-treated cells was calculated as fold change over the baseline activity detected in control cultures treated with DMSO-containing media.
Table 1
[0100] Table 1 indicates that Compound 11 and Compound 12 are able to activate ARE- dependent signaling of the luciferase reporter construct. This suggests the compounds are able to activate the Nrf2 signaling cascade and induce expression of genes downstream of the ARE.
EXAMPLE 6
In vivo evaluation of Nrf2 activation
[0101] Test compounds were dosed either in suspension of 0.8% HPMC or corn oil via oral gavage to male SD rats (average weight of 250 mg, 6 animals per group, two groups), at a dose of 100 mg/kg equivalent of DMF (dosing volume: 5 ml/kg). After 30 minutes, the first group of animals was sacrificed via C02 asphyxiation. 1.0 mL blood sample via cardiac bleed pipetted into chilled lithium heparin tubes with 10 mg sodium fluoride. Samples were centrifuged within 30 minutes at 4 °C for 15 minutes at 1500G and plasma was transferred to chilled tubes and immediately frozen on dry ice, further kept at -70 °C until shipment for analysis. Brain was removed; sections were weighed and frozen until analysis. Brain and plasma samples were analyzed for monomethylfumaric acid ester (MMF) exposure. After 6 h, the second group of animals was sacrificed via C02 asphyxiation. Brain, spleen, liver and jejunum were removed, flash frozen and placed on dry ice and maintained frozen until analysis. Sections of brain, spleen, liver, and jejunum were submitted for qPCR analysis of relative expression increase of Nrf2 responsive enzymes such as NQO-1, Akrlb8, and Sulfiredoxin-1.
[0102] Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulation and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.
Claims
WHAT IS CLAIMED IS:
A compound having Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R is Ci-Cio alkyl, C6-Cio aryl, hydroxyl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl;
each of R3, R4, and R5, independently, is C1-C10 alkyl, C6-Cio aryl, hydroxyl, -O-Ci-Cio alkyl, -O-C6-C10 aryl, or
wherein R is C1-C24 alkyl or C6-Cio aryl; each of which can be optionally substituted; and
each of m, n, and r, independently, is 0-4;
2. The compound of claim 1 having Formula II:
2 3
each of, independently, R and R , is C1-C10 alkyl or C6-Cio aryl;
2 3
R" and RJ can be the same or different, can be optionally substituted, and independently can be selected from the group consisting of C1-C10 alkyl or C6-Cio aryl.
The compound of claim 2, wherein each of R 2 and R 3 , independently, is methyl, ethyl, or isopropyl.
The compound of claim 2, wherein R1 is methyl, ethyl, or isopropyl. The compound of claim 1 having Formula III:
R1 is C1-C24 alkyl or C6-Cio aryl;
2 3 5
each of R , R , and R , independently, is hydroxyl, C1-C10 alkyl, C6-Cio aryl, -O-Ci-Cio alkyl, or -O-C6-C10 aryl; and
n is 1 or 2.
2 3 5
The compound of claim 5, wherein each of R , R , and R , independently, is hydroxyl, methoxy, ethoxy, methyl, or ethyl.
The compound of claim 5, wherein n is 1.
The compound of claim 1 having Formula IV:
R1 is C1-C24 alkyl or C6-Cio aryl; and
R2 is C1-C10 alkyl.
9. The compound of claim 8, wherein R is methyl, ethyl, or isopropyl.
10. The compound of claim 8, wherein each R1, independently, is methyl, ethyl, or isopropyl.
11. The compound of claim 1 , selected from the group consisting of:
(dimethylsilanediyl)dimethyl difumarate;
methyl ((trimethoxysilyl)methyl) fumarate;
methyl ((trihydroxysilyl)methyl) fumarate; and
trimethyl (methylsilanetriyl) trifumarate.
12. A method of treating a subject having a condition characterized by at least one symptom chosen from neurodegeneration and neuroinflammation comprising administering to a subject a compound of claim 1, claim 2, claim 5, claim 8, or claim 1 1.
13. The method of claim 12, wherein the condition characterized by at least symptom chosen from neurodegeneration and neuroinflammation is multiple sclerosis, Huntington's disease, Amytrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.
14. The method of claim 12, wherein the compound is administered in an amount from about 100 mg to about 800 mg per day.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/363,546 US9421273B2 (en) | 2011-12-16 | 2012-12-14 | Silicon-containing fumaric acid esters |
EP12856877.1A EP2791181A4 (en) | 2011-12-16 | 2012-12-14 | Silicon-containing fumaric acid esters |
HK15103505.5A HK1202885A1 (en) | 2011-12-16 | 2015-04-09 | Silicon-containing fumaric acid esters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161576828P | 2011-12-16 | 2011-12-16 | |
US61/576,828 | 2011-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013090799A1 true WO2013090799A1 (en) | 2013-06-20 |
Family
ID=48613236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/069872 WO2013090799A1 (en) | 2011-12-16 | 2012-12-14 | Silicon-containing fumaric acid esters |
Country Status (4)
Country | Link |
---|---|
US (1) | US9421273B2 (en) |
EP (1) | EP2791181A4 (en) |
HK (1) | HK1202885A1 (en) |
WO (1) | WO2013090799A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US8980832B2 (en) | 2003-09-09 | 2015-03-17 | Biogen Idec International Gmbh | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
WO2016153957A3 (en) * | 2015-03-20 | 2016-11-10 | Biogen Ma Inc. | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
US9505776B2 (en) | 2013-03-14 | 2016-11-29 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9566259B1 (en) | 2015-08-31 | 2017-02-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US10399924B2 (en) | 2012-12-21 | 2019-09-03 | Biogen Ma Inc. | Deuterium substituted fumarate derivatives |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2334378T3 (en) | 2008-08-19 | 2014-09-30 | Xenoport Inc | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
JP2015526477A (en) | 2012-08-22 | 2015-09-10 | ゼノポート,インコーポレイティド | Oral dosage form of methylhydrogen fumarate and its prodrug |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060241240A1 (en) * | 2003-03-26 | 2006-10-26 | Marcel Vos | Process for the preparation of poly(silyl ester)s, and their uses |
US20090011986A1 (en) * | 2005-05-18 | 2009-01-08 | Rajendra Kumar Joshi | Thiosuccinic Acid Derivatives and the Use Thereof |
US20090306015A1 (en) * | 2005-12-20 | 2009-12-10 | Silamed, Inc. | Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds |
WO2010126605A1 (en) * | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0812340B2 (en) | 1986-04-07 | 1996-02-07 | 日本油脂株式会社 | contact lens |
JP2805794B2 (en) | 1988-05-06 | 1998-09-30 | エヌオーケー株式会社 | Manufacturing method of gas separation membrane |
JP2790021B2 (en) * | 1993-09-30 | 1998-08-27 | 日本油脂株式会社 | Paint composition |
ES2916604T1 (en) | 2007-02-08 | 2022-07-04 | Biogen Ma Inc | Nrf2 Detection Assays and Related Methods and Compositions |
DE102007042948A1 (en) | 2007-09-10 | 2009-03-12 | Wacker Chemie Ag | Moisture-crosslinkable polymers based on α-heteroatom-substituted silanes |
DE102008002163A1 (en) | 2008-06-02 | 2009-12-03 | Wacker Chemie Ag | Binders based on polymers containing alpha-silane groups |
-
2012
- 2012-12-14 US US14/363,546 patent/US9421273B2/en not_active Expired - Fee Related
- 2012-12-14 WO PCT/US2012/069872 patent/WO2013090799A1/en active Application Filing
- 2012-12-14 EP EP12856877.1A patent/EP2791181A4/en not_active Withdrawn
-
2015
- 2015-04-09 HK HK15103505.5A patent/HK1202885A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060241240A1 (en) * | 2003-03-26 | 2006-10-26 | Marcel Vos | Process for the preparation of poly(silyl ester)s, and their uses |
US20090011986A1 (en) * | 2005-05-18 | 2009-01-08 | Rajendra Kumar Joshi | Thiosuccinic Acid Derivatives and the Use Thereof |
US20090306015A1 (en) * | 2005-12-20 | 2009-12-10 | Silamed, Inc. | Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds |
WO2010126605A1 (en) * | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
Non-Patent Citations (1)
Title |
---|
See also references of EP2791181A4 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980832B2 (en) | 2003-09-09 | 2015-03-17 | Biogen Idec International Gmbh | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
US10399924B2 (en) | 2012-12-21 | 2019-09-03 | Biogen Ma Inc. | Deuterium substituted fumarate derivatives |
US9505776B2 (en) | 2013-03-14 | 2016-11-29 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US12076306B2 (en) | 2013-03-14 | 2024-09-03 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11905298B2 (en) | 2013-03-14 | 2024-02-20 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11679092B2 (en) | 2013-03-14 | 2023-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11230548B2 (en) | 2013-03-14 | 2022-01-25 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US11083703B2 (en) | 2013-03-14 | 2021-08-10 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10596140B2 (en) | 2013-03-14 | 2020-03-24 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US10406133B2 (en) | 2013-03-14 | 2019-09-10 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9090558B2 (en) | 2013-03-14 | 2015-07-28 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9604922B2 (en) | 2014-02-24 | 2017-03-28 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US9820960B2 (en) | 2014-02-28 | 2017-11-21 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918616B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9511043B2 (en) | 2014-02-28 | 2016-12-06 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10105337B2 (en) | 2014-02-28 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10105336B2 (en) | 2014-02-28 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US9517209B2 (en) | 2014-02-28 | 2016-12-13 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918617B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918615B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate esters |
US9814691B2 (en) | 2014-02-28 | 2017-11-14 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
WO2016153957A3 (en) * | 2015-03-20 | 2016-11-10 | Biogen Ma Inc. | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
US9566259B1 (en) | 2015-08-31 | 2017-02-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10945985B2 (en) | 2015-08-31 | 2021-03-16 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9636319B1 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10105335B2 (en) | 2015-08-31 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US11590095B2 (en) | 2015-08-31 | 2023-02-28 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9814692B2 (en) | 2015-08-31 | 2017-11-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9820961B2 (en) | 2015-08-31 | 2017-11-21 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Also Published As
Publication number | Publication date |
---|---|
HK1202885A1 (en) | 2015-10-09 |
EP2791181A1 (en) | 2014-10-22 |
US20140336151A1 (en) | 2014-11-13 |
US9421273B2 (en) | 2016-08-23 |
EP2791181A4 (en) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9421273B2 (en) | Silicon-containing fumaric acid esters | |
AU2018260937B2 (en) | Pharmaceutical compositions containing dimethyl fumarate | |
TW384288B (en) | 5-substituted derivatives of mycophenolic acid | |
WO1996006068A1 (en) | Benzene compound and medicinal use thereof | |
US9862721B2 (en) | Tetrahydrocarboline derivative | |
CN102906090A (en) | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | |
TW200813055A (en) | Spiro-conjugated cyclic group containing compound and use thereof | |
WO2015128492A1 (en) | Monomethyl- and dimethylfumarate for nk cell activation | |
EP3419959A1 (en) | Combination therapy | |
CN106660992B (en) | Dimethylpyridine derivative and medical application thereof | |
CA2931064C (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
CA3079042A1 (en) | D-amino acid oxidase inhibitors and therapeutic uses thereof | |
KR20000065102A (en) | Inhibition of vascular cell adsorption molecule-1 using 2,6-di-alkyl-4-silyl-phenol and treatment of chronic inflammatory diseases | |
CN114656453B (en) | Heptamethine indocyanine-TEMPO chemical even chain small molecule, preparation method and application thereof in preparation of radiation protection preparation | |
TWI537245B (en) | Compounds for use in the treatment of autoimmune inflammatory disease | |
US20220259164A1 (en) | Use of aminothiol compounds as cerebral nerve or heart protective agent | |
CN101081853A (en) | 7-phenylpyrazolopyridine compounds | |
JPH0764727B2 (en) | Anticonvulsant compounds and methods of use thereof | |
US9428431B2 (en) | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | |
CN113387864B (en) | S-indole benzamide derivative and preparation method and application thereof | |
JP7348214B2 (en) | Crystal forms of HDAC6 selective inhibitors and uses thereof | |
JP2011509994A (en) | Tetrahydrocyclopenta [c] acridine derivatives as kinase inhibitors and their biological applications | |
WO2017198159A1 (en) | Imidazole derivative containing bridge ring | |
US20180215703A1 (en) | Stearoyl amino acid salt and method of use thereof | |
JPH0680563A (en) | Anti-hyperlipemia agent and anti-arteriosclerosis agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12856877 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14363546 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2012856877 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012856877 Country of ref document: EP |